These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38388662)

  • 1. Machine learning using clinical data at baseline predicts the medium-term efficacy of ustekinumab in patients with ulcerative colitis.
    Morikubo H; Tojima R; Maeda T; Matsuoka K; Matsuura M; Miyoshi J; Tamura S; Hisamatsu T
    Sci Rep; 2024 Feb; 14(1):4386. PubMed ID: 38388662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Machine learning using clinical data at baseline predicts the efficacy of vedolizumab at week 22 in patients with ulcerative colitis.
    Miyoshi J; Maeda T; Matsuoka K; Saito D; Miyoshi S; Matsuura M; Okamoto S; Tamura S; Hisamatsu T
    Sci Rep; 2021 Aug; 11(1):16440. PubMed ID: 34385588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of ustekinumab vs. advanced therapies for the treatment of moderately to severely active ulcerative colitis: a systematic review and network meta-analysis.
    Welty M; Mesana L; Padhiar A; Naessens D; Diels J; van Sanden S; Pacou M
    Curr Med Res Opin; 2020 Apr; 36(4):595-606. PubMed ID: 31960724
    [No Abstract]   [Full Text] [Related]  

  • 4. Prior Immunogenicity to Anti-TNF Biologics Is Not Associated with Increased Anti-drug Antibodies to Vedolizumab or Ustekinumab.
    Costable NJ; Borman ZA; Ji J; Dubinsky MC; Ungaro RC
    Dig Dis Sci; 2022 Jun; 67(6):2480-2484. PubMed ID: 34021427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world Endoscopic and Histological Outcomes Are Correlated with Ustekinumab Exposure in Patients with Ulcerative Colitis.
    Alsoud D; De Hertogh G; Compernolle G; Tops S; Sabino J; Ferrante M; Thomas D; Vermeire S; Verstockt B
    J Crohns Colitis; 2022 Nov; 16(10):1562-1570. PubMed ID: 35533353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual biologic therapy for severe ulcerative colitis, concomitant extraintestinal manifestations and an orbital osteoma: a successful treatment.
    Peter CD; Huang YH; Tian WN
    Rev Esp Enferm Dig; 2022 Dec; 114(12):757-758. PubMed ID: 35770593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real-world cohort study.
    Amiot A; Filippi J; Abitbol V; Cadiot G; Laharie D; Serrero M; Altwegg R; Bouhnik Y; Peyrin-Biroulet L; Gilletta C; Roblin X; Pineton de Chambrun G; Vuitton L; Bourrier A; Nancey S; Gornet JM; Nahon S; Bouguen G; Viennot S; Pariente B; Fumery M;
    Aliment Pharmacol Ther; 2020 Jun; 51(11):1039-1046. PubMed ID: 32291786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative real-world effectiveness of vedolizumab and ustekinumab for patients with ulcerative colitis: a GETAID multicentre cohort study.
    Meyer A; Fumery M; Peyrin-Biroulet L; Filippi J; Altwegg R; Bouhnik Y; Serrero M; Laharie D; Roblin X; Nachury M; Abitbol V; Cadiot G; Nancey S; Allez M; Gilletta C; Vuitton L; Savoye G; Nahon S; Bourrier A; Buisson A; Bouguen G; Bourreille A; Viennot S; Carbonnel F; Amiot A
    Scand J Gastroenterol; 2022 Dec; 57(12):1454-1462. PubMed ID: 35819361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. One-year outcomes with ustekinumab therapy in infliximab-refractory paediatric ulcerative colitis: a multicentre prospective study.
    Dhaliwal J; McKay HE; Deslandres C; Debruyn J; Wine E; Wu A; Huynh H; Carman N; Crowley E; Church PC; Walters TD; Ricciuto A; Griffiths AM;
    Aliment Pharmacol Ther; 2021 Jun; 53(12):1300-1308. PubMed ID: 33909911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effectiveness of ustekinumab and vedolizumab as third-line biologic therapy in patients with Crohn's disease.
    Macaluso FS; Grova M; Saladino M; Cappello M; Demarzo MG; Privitera AC; Giangreco E; Garufi S; Renna S; Casà A; Ventimiglia M; Fries W; Orlando A;
    Dig Liver Dis; 2023 Apr; 55(4):471-477. PubMed ID: 36127230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Network meta-analysis on efficacy and safety of different biologics for ulcerative colitis.
    Chu X; Biao Y; Liu C; Zhang Y; Liu C; Ma JZ; Guo Y; Gu Y
    BMC Gastroenterol; 2023 Oct; 23(1):346. PubMed ID: 37803294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab.
    Hu A; Kotze PG; Burgevin A; Tan W; Jess A; Li PS; Kroeker K; Halloran B; Panaccione R; Peyrin-Biroulet L; Ma C; Ananthakrishnan AN
    Clin Gastroenterol Hepatol; 2021 Jul; 19(7):1366-1376.e2. PubMed ID: 32668338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of ustekinumab in treatment of ulcerative colitis: a narrative review.
    Grova M; Vitello A; Mannino M; Casà A; Renna S; Macaluso FS; Orlando A
    Immunotherapy; 2023 Dec; 15(18):1539-1552. PubMed ID: 38018475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ustekinumab safety and effectiveness in patients with ulcerative colitis: results from a large real-life study.
    Tursi A; Mocci G; Scaldaferri F; Napolitano D; Maresca R; Pugliese D; Semprucci G; Savarino E; Cuomo A; Donnarumma L; Bodini G; Pasta A; Maconi G; Cataletti G; Pranzo G; Rodinò S; Sebkova L; Costa F; Ferronato A; Gaiani F; Marzo M; Luppino I; Fabiano G; Paese P; Elisei W; Monterubbianesi R; Faggiani R; Grossi L; Serio M; Scarcelli A; Lorenzetti R; Allegretta L; Chiri S; Grasso G; Antonelli E; Bassotti G; Spagnuolo R; Luzza F; Fanigliulo L; Rocco G; Sacchi C; Zampaletta C; Rocchi C; Bolognini L; Bendia E; Bianco MA; Capone P; Meucci C; Colucci R; Tonti P; Neve V; Della Valle N; Felice C; Pica R; Cocco A; Forti G; Onidi FM; Usai Satta P; Checchin D; Gravina AG; Pellegrino R; Picchio M; Papa A
    Expert Opin Biol Ther; 2024; 24(1-2):101-109. PubMed ID: 38250818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The diagnostic and evaluation value of plasma interleukin 9 in the mucosal healing in patients with inflammatory bowel disease treated with biological agents].
    Ye YL; Hu T; Xu LJ; Zhang LP; Yin J; Yu Q; Pang Z
    Zhonghua Yi Xue Za Zhi; 2023 May; 103(19):1483-1489. PubMed ID: 37198111
    [No Abstract]   [Full Text] [Related]  

  • 16. Ustekinumab Decreases Circulating Th17 Cells in Ulcerative Colitis.
    Imazu N; Torisu T; Ihara Y; Umeno J; Kawasaki K; Fujioka S; Fuyuno Y; Matsuno Y; Moriyama T; Kitazono T
    Intern Med; 2024 Jan; 63(2):153-158. PubMed ID: 37197955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vedolizumab, an option in patients with inflammatory bowel disease intolerant to thiopurines and refractory to biological agents.
    Iborra M; Beltrán B; Maroto N; Navarro-Cortés P; Boscá-Watts M; Ferrer-Bradley I; García-Morales N; Sáez-González E; Hinojosa J; Mínguez M; Nos P
    Gastroenterol Hepatol; 2018 Nov; 41(9):535-543. PubMed ID: 30031573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment persistence of ustekinumab and vedolizumab in IBD patients is independent of prior immunogenicity to anti-TNFs: a retrospective study.
    Blesl A; Petritsch W; Binder L; Fürst S; Wenzl H; Baumann-Durchschein F; Kump P; Högenauer C
    Scand J Gastroenterol; 2022 Nov; 57(11):1327-1330. PubMed ID: 35732583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes with ustekinumab as rescue treatment in therapy-refractory or therapy-intolerant ulcerative colitis.
    Ochsenkühn T; Tillack C; Szokodi D; Janelidze S; Schnitzler F
    United European Gastroenterol J; 2020 Feb; 8(1):91-98. PubMed ID: 32213052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vedolizumab as the First-Line of Biologicals for Pediatric Patients With Ulcerative Colitis.
    Kakiuchi T; Yoshiura M
    Clin Ther; 2022 Jul; 44(7):1028-1032. PubMed ID: 35779956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.